Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

NAActive, not recruitingINTERVENTIONAL
Enrollment

20,000

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 10, 2028

Study Completion Date

May 10, 2029

Conditions
Weight LossMetabolic SyndromeDiabetes Mellitus, Type 2Central ObesityInsulin ResistanceGlucose IntoleranceMetabolic Glucose Disorders
Interventions
DEVICE

Continuous Glucose Monitor Device

Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.

Trial Locations (1)

94306

Signos, Palo Alto

All Listed Sponsors
lead

Signos Inc

INDUSTRY

NCT05874635 - Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022) | Biotech Hunter | Biotech Hunter